| Medicines/Item |
Section |
Status |
Link Name / Link URL |
| Abatacept |
10.01.03 |
Restricted Use
|
NICE TA375: Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying antirheumatic drugs |
| Abatacept |
10.01.03 |
Restricted Use
|
NICE TA373: Abatcept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Abiraterone Actetate |
08.03.04.02 |
Restricted Use
|
NICE TA 259: Abiraterone for castration resistant prostate cancer |
| Adalimumab |
13.05.03 |
Restricted Use
|
NICE TA 146: Psoriasis-adalimumab |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA383: TNF alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Adalimumab |
01.05.03 |
Restricted Use
|
NICE TA187: Crohns disease - infliximab (review) and adalimumab (review of TA40) |
| Adefovir Dipivoxil |
05.03.03 |
Non Formulary
|
NICE TA96: Adefovir dipivoxil and pegylated interferon alpha-2a for the treatment of chronic hepatitis B |
| Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA346: Aflibercept for treating diabetic macular oedema |
| Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA 409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion |
| Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion |
| Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA 294: Macular degeneration (wet age-related) - aflibercept |
| Alemtuzumab |
08.02.03 |
Restricted Use
|
NICE TA312: Alemtuzumab for treating relapsing-remitting multiple sclerosis |
| Alirocumab |
02.12 |
Restricted Use
|
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Alitretinoin |
13.05.01 |
Formulary
|
NICE TA177: Eczema (chronic) - alitretinoin |
| Alteplase |
02.10.02 |
Restricted Use
|
NICE TA264: Ischaemic stroke (acute) - alteplase |
| Anakinra |
10.01.03 |
Restricted Use
|
NICE CG79: Rheumatoid arthritis: the management of rheumatoid arthritis in adults |
| Anti-D (Rh0) Immunoglobulin |
14.05.03 |
Formulary
|
NICE TA156: Anti-D in pregnant women |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA 245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA275: Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA 341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
| Apomorphine |
04.09.01 |
Restricted Use
|
NG71 Parkinson’s disease in adults |
| Apremilast |
13.05.03 |
Restricted Use
|
NICE TA 419: Apremilast for treating moderate to severe plaque psoriasis |
| Apremilast |
13.05.03 |
Restricted Use
|
NICE TA 433: Apremilast for treating active psoriatic arthritis |
| Aripiprazole |
04.02.01 |
Non Formulary
|
NICE TA 292: Bipolar disorder (adolescents) - aripiprazole |
| Aripiprazole |
04.02.01 |
Non Formulary
|
NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15-17 years |
| Atezolizumab |
08.02.03 |
Restricted Use
|
NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
| Atezolizumab |
08.02.03 |
Restricted Use
|
NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer |
| Atezolizumab |
08.02.03 |
Restricted Use
|
NICE TA639:Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer |
| Azacitidine |
08.01.03 |
Non Formulary
|
NICE TA218: azacitidine for myelodysplastic syndromes |
| Baricitinib |
10.01.03 |
Restricted Use
|
NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis |
| Bendamustine |
08.01.01 |
Non Formulary
|
NICE TA216: Bendamustine for CLL |
| Bevacizumab |
08.01.05 |
Non Formulary
|
NICE TA214: Breast Cancer with taxane |
| Bevacizumab |
08.01.05 |
Non Formulary
|
NICE TA263: Breast cancer with capecitabine |
| Bevacizumab |
08.01.05 |
Non Formulary
|
NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer |
| Bivalirudin |
02.08.01 |
Restricted Use
|
NICE TA230: Bivalirudin for the treatment of STEMI, 2011 |
| Blinatumomab |
08.02.03 |
Restricted Use
|
NICE TA450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia |
| Boceprevir |
05.03.03 |
Non Formulary
|
NICE TA253: Boceprevir for the treatment of genotype 1 chronic hepatitis C |
| Bortezomib |
08.01.05 |
Non Formulary
|
NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma |
| Bortezomib |
08.01.05 |
Non Formulary
|
NICE TA129: Multiple myeloma - bortezomib |
| Botulinum Toxin Type A |
04.09.03 |
Restricted Use
|
NICE TA260: Botox for migraine prophylaxis |
| Botulinum Toxin Type A |
04.09.03 |
Restricted Use
|
NICE TA 605 Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea |
| Brentuximab vedotin |
08.02.03 |
Restricted Use
|
TA478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma |
| Brentuximab vedotin |
08.02.03 |
Restricted Use
|
TA542 Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma |
| Brentuximab vedotin |
08.02.03 |
Restricted Use
|
TA577 Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma |
| Brigatinib |
08.02 |
Formulary
|
NICE TA571-Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib |
| Brodalumab |
13.05.03 |
Formulary
|
NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis |
| Cabazitaxel |
08.01.05 |
Non Formulary
|
NICE TAG 255: Cabazitaxel for prostate cancer |
| Capecitabine |
08.01.03 |
Non Formulary
|
NICE TA60: Colorectal cancer - capecitabine and tegafur uracil |
| Capecitabine |
08.01.03 |
Non Formulary
|
NICE TA191: Gastric cancer (advanced) - capecitabine |
| Capecitabine |
08.01.03 |
Non Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
| Carmustine |
08.01.01 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Carmustine |
08.01.01 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis - certolizumab pegol |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA 415: Certolizumab Pegol for treating rheumatoid arthritis after an inadequate response to a TNF-alpha inhibitor. |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Cetuximab |
08.01.05 |
Non Formulary
|
NICE TA176: Colorectal cancer (first line) - cetuximab |
| Cetuximab |
08.01.05 |
Non Formulary
|
NICE TA172: Head and neck cancer (squamous cell carcinoma) - cetuximab |
| Cetuximab |
08.01.05 |
Non Formulary
|
NICE TA145: Head and neck cancer - cetuximab |
| Cetuximab |
08.01.05 |
Non Formulary
|
NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab |
| Cinacalcet |
09.05.01.02 |
Non Formulary
|
NICE TA117: Hyperparathyroidism - cinacalcet |
| Cladribine |
08.02.04 |
Restricted Use
|
NICE TA493: Cladribine tablets for treating relapsing-remitting multiple sclerosis |
| Collagenase clostridium histolytium |
10.03.01 |
Restricted Use
|
NICE TA459: Collagenase clostridium histolyticum for treating Dupuytren’s contracture |
| Dabigatran etexilate |
02.08.02 |
Non Formulary
|
NICE TA249: Dabigatran for Stroke prevention in AF |
| Dabigatran etexilate |
02.08.02 |
Non Formulary
|
NICE TA157: Dabigatran etexilate for prevention of venous thromboembolism after hip or knee replacement surgery in adults |
| Daclizumab |
08.02.02 |
Non Formulary
|
Daclizumab for treating relapsing-remitting multiple sclerosis |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA597 - Dapagliflozin with insulin for treating type 1 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA288 - Dapagliflozin in combination therapy for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390 - Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA418 - Dapagliflozin in triple therapy for treating type 2 diabetes |
| Daratumumab |
08.02.03 |
Formulary
|
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma |
| Daratumumab |
08.02.03 |
Formulary
|
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma |
| Dasatinib |
08.01.05 |
Non Formulary
|
NICE TA241:CML for whom treatment with imatinib has failed because of intolerance |
| Denosumab |
06.06.02 |
Restricted Use
|
NICE TA204: Osteoporotic fractures - denosumab |
| Denosumab |
06.06.02 |
Restricted Use
|
NICE TA265: Denosumab for the prevention of skeletal-related events in adults with metastases from solid tumours |
| Dexamethasone |
11.04.01 |
Restricted Use
|
NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema |
| Dexamethasone |
11.04.01 |
Restricted Use
|
NICE TA349: Dexamethasone intravitreal implant for the treatment of diabetic macular oedema |
| Dimethyl Fumarate |
08.02.04 |
Restricted Use
|
NICE TA 320: Dimethyl Fumarate for treating relapsing remitting multiple sclerosis |
| Dimethyl fumarate |
13.05.03 |
Restricted Use
|
NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis |
| Docetaxel |
08.01.05 |
Non Formulary
|
NICE TA101: Prostate cancer (hormone-refractory) - docetaxel |
| Docetaxel |
08.01.05 |
Non Formulary
|
NICE TA109: Breast cancer (early) - docetaxel |
| Doxorubicin Hydrochloride |
08.01.02 |
Non Formulary
|
NICE TA91: Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review) |
| Dronedarone |
02.03.02 |
Formulary
|
NICE TA197: Atrial fibrillation - dronedarone |
| Dupilumab |
13.05.03 |
Restricted Use
|
NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis |
| Durvalumab |
08.02.03 |
Restricted Use
|
NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platimum based chemoradiation |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA354: Edoxaban for treating and preventing DVT and PE |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA355: Edoxaban for preventing stroke and systemic embolism in patients with non-valvular AF |
| Eltrombopag |
09.01.04 |
Restricted Use
|
NICE TA 293: Thrombocytopenic purpura - Eltrombopag |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA336 - Empagliflozin in combination therapy for treating type 2 diabetes |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390 - Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Encorafenib |
08.02 |
Formulary
|
NICE TA668-Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer |
| Entecavir |
05.03.03 |
Non Formulary
|
NICE TA153: Entecavir for the treatment of chronic hepatitis B |
| Eplerenone |
02.02.03 |
Formulary
|
NICE CG108: Chronic heart failure |
| Erlotinib |
08.01.05 |
Non Formulary
|
NICE TA162: Lung cancer (non-small-cell) 2nd line- erlotinib |
| Erlotinib |
08.01.05 |
Non Formulary
|
NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Etanercept |
13.05.03 |
Restricted Use
|
NICE TA103: Psoriasis - efalizumab and etanercept |
| Everolimus |
08.01.05 |
Non Formulary
|
NICE TA 295: Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor) |
| Everolimus |
08.01.05 |
Non Formulary
|
NICE TA219: Everolimus for second-line treatment of renal cell cancer |
| Evolocumab |
02.12 |
Restricted Use
|
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Ezetimibe |
02.12 |
Restricted Use
|
NICE TA132: Hypercholesterolaemia - ezetimibe |
| Febuxostat |
10.01.04 |
Restricted Use
|
NICE TA164: Hyperuricaemia - febuxostat |
| Finasteride |
06.04.02 |
Formulary
|
NICE CG97: Lower urinary tract symptoms in men |
| Fingolimod |
08.02.04 |
Restricted Use
|
NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis |
| Fludarabine Phosphate |
08.01.03 |
Non Formulary
|
NICE TA29: Leukaemia (lymphocytic) - fludarabine |
| Fludarabine Phosphate |
08.01.03 |
Non Formulary
|
NICE TA119: Leukaemia (lymphocytic) - fludarabine |
| Fluocinolone |
11.04.01 |
Restricted Use
|
NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of TA271) |
| Fremanezumab |
04.07.04.02 |
Restricted Use
|
NICE TA631-Fremanezumab for preventing migraine |
| Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer |
| Gefitinib |
08.01.05 |
Non Formulary
|
NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib |
| Gemcitabine |
08.01.03 |
Non Formulary
|
NICE TA116: Breast cancer - gemcitabine |
| Gemcitabine |
08.01.03 |
Non Formulary
|
NICE TA25: Pancreatic cancer - gemcitabine |
| Gilteritinib |
08.02 |
Formulary
|
NICE TA642-Gilteritinib for treating relapsed or refractory acute myeloid leukaemia |
| GLIADEL wafer Carmustine 7.6mg |
20 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA220: Psoriatic arthritis - golimumab |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis - golimumab |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA329: Ulcerative colitis - golimumab |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA383: Ankylosing spondylitis - golimumab |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA225: Rheumatoid arthritis treatment after conventional DMARDs - golimumab |
| Guselkumab |
13.05.03 |
Restricted Use
|
NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis |
| Imatinib |
08.01.05 |
Non Formulary
|
NICE TA86: Gastro-intestinal stromal tumours (GIST) - imatinib |
| Imatinib |
08.01.05 |
Non Formulary
|
NICE TA209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib |
| Imatinib |
08.01.05 |
Non Formulary
|
NICE TA70: Leukaemia (chronic myeloid) - imatinib |
| Infliximab |
01.05.03 |
Restricted Use
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
| Infliximab |
01.05.03 |
Restricted Use
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderatley to severely active ulcerative colitis after the failure of conventional therapy |
| Infliximab |
01.05.03 |
Restricted Use
|
NICE TA187: Crohns disease - infliximab (review) and adalimumab (review of TA40) |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA383: TNF alpha inhibitors for ankylosing spondylitis and non-radiologic axial spondyloarthritis |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab |
| Infliximab |
13.05.03 |
Restricted Use
|
NICE TA134: Infliximab for psoriasis |
| Inotuzumab ozogamicin |
08.02.03 |
Restricted Use
|
NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia |
| Isatuximab |
08.02.03 |
Restricted Use
|
NICE TA658-Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma |
| Ivabradine |
02.06.03 |
Restricted Use
|
NICE TA267: Ivabradine for treating chronic heart failure |
| Ixekizumab |
10.01.03 |
Restricted Use
|
NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Ixekizumab |
13.05.03 |
Restricted Use
|
NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis |
| Lapatinib |
08.01.05 |
Non Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Lorlatinib |
08.01 |
Non Formulary
|
Lorlatinib for previously treated ALK +VE ADVANCED nsclc |
| Lorlatinib |
08.02 |
Formulary
|
Previously treated ALK +ve advanced NSCLC NICE TA 628 |
| Lubiprostone |
01.02 |
Non Formulary
|
NICE TA318: Lubiprostone for treating chronic idiopathic constipation |
| Mannitol inhalation |
03.07 |
Non Formulary
|
NICE TA266: Mannitol dry powder for inhalation for treating cystic fibrosis |
| Mepolizumab |
03.04.02 |
Restricted Use
|
NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma |
| Mirabegron |
07.04.02 |
Non Formulary
|
NICE TA 290: Overactive bladder - mirabegron |
| Naltrexone Hydrochloride |
04.10.03 |
Non Formulary
|
NICE TA115: Naltrexone for the management of opioid dependence |
| Natalizumab |
08.02.04 |
Restricted Use
|
NICE TA127: Multiple sclerosis - natalizumab |
| Nilotinib |
08.01.05 |
Non Formulary
|
NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML |
| Niraparib |
08.02 |
Formulary
|
NICE TA528 Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer |
| Niraparib |
08.02 |
Formulary
|
NG161-COVID-19 rapid guideline: delivery of systemic anticancer treatments |
| Niraparib |
08.02 |
Formulary
|
NICE TA673-Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy |
| Obinutuzumab |
08.02.03 |
Restricted Use
|
NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia |
| Obinutuzumab |
08.02.03 |
Restricted Use
|
NICE TA663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia |
| Ocrelizumab |
08.02.03 |
Restricted Use
|
NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis |
| Ocrelizumab |
08.02.03 |
Restricted Use
|
NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis |
| Ofatumumab |
08.02.03 |
Restricted Use
|
NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia |
| Olaparib |
08.02 |
Formulary
|
TA598- Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy |
| Olaparib |
08.02 |
Formulary
|
TA620-Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
| Olaparib |
08.02 |
Formulary
|
NG161-COVID-19 rapid guideline: delivery of systemic anticancer treatments |
| Omalizumab |
03.04.02 |
Restricted Use
|
NICE TA278: Omalizumab for treating severe persistant allergic asthma (review of TA133 and TA201) |
| Omalizumab |
03.04.02 |
Restricted Use
|
NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria |
| Osimertinib |
08.02 |
Formulary
|
NICE TA654 Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer |
| Oxaliplatin |
08.01.05 |
Non Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
| Paclitaxel |
08.01.05 |
Non Formulary
|
NICE TA55: Ovarian cancer - paclitaxel (review) |
| Paclitaxel |
08.01.05 |
Non Formulary
|
NICE TA108: Breast cancer (early) - paclitaxel |
| Patiromer |
09.02.01.01 |
Restricted Use
|
Patiromer for treating hyperkalaemia TA623 |
| Pazopanib |
08.01.05 |
Non Formulary
|
NICE TA215: Renal cell carcinoma (first line metastatic) - pazopanib |
| Pegaptanib Sodium |
11.08.02 |
Non Formulary
|
NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. |
| Peginterferon Alfa |
08.02.04 |
Restricted Use
|
NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people |
| Peginterferon Alfa |
08.02.04 |
Restricted Use
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
| Peginterferon Alfa |
08.02.04 |
Restricted Use
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
| Peginterferon Alfa |
08.02.04 |
Restricted Use
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people |
| Pemetrexed |
08.01.03 |
Non Formulary
|
NICE TA135: Mesothelioma - pemetrexed disodium |
| Pemetrexed |
08.01.03 |
Non Formulary
|
NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance) |
| Pemetrexed |
08.01.03 |
Non Formulary
|
NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed |
| Pentosan Polysulphate |
07.04.03 |
Formulary
|
NICE TA 610 |
| Pimecrolimus 1% cream |
13.05.03 |
Restricted Use
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Polatuzumab vedotin |
08.02.03 |
Restricted Use
|
TA649 Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma |
| Prasugrel |
02.09 |
Restricted Use
|
NICE TA317: Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182) |
| Prucalopride |
01.06.07 |
Restricted Use
|
NICE TA211: Prucalopride for the treatment of chronic constipation in women |
| Raloxifene Hydrochloride |
06.04.01.01 |
Non Formulary
|
NICE quick reference guide on osteoporosis |
| Ranibizumab |
11.08.02 |
Restricted Use
|
NICE TA283: macular oedema secondary to retinal vein occlusion |
| Ranibizumab |
11.08.02 |
Restricted Use
|
NICE TA298: Ranibizumab for treating choroidal neovascularisation associated with pathlogical myopia |
| Ranibizumab |
11.08.02 |
Restricted Use
|
NICE TA155: age-related macular degeneration |
| Ranibizumab |
11.08.02 |
Restricted Use
|
NICE TA274: diabetic macular oedema |
| Reslizumab |
03.04.02 |
Restricted Use
|
NICE TA479: Reslizumab for treating severe eosinophilic asthma |
| Retigabine |
04.08.01 |
Restricted Use
|
NICE TA232 - Retigabine for the adjunctive treatment of partial onset seizures in epilepsy |
| Ribavirin |
05.03.05 |
Non Formulary
|
NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C |
| Ribavirin |
05.03.05 |
Non Formulary
|
NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C |
| Ribavirin |
05.03.05 |
Non Formulary
|
NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people |
| Ribavirin |
05.03.05 |
Non Formulary
|
NICE TA75: Interferon alfa and ribavirin for the treatment of chronic hepatitis C |
| Rifaximin |
05.01.07 |
Formulary
|
NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy. |
| Riluzole |
04.09.03 |
Restricted Use
|
NICE TA20: Motor neurone disease - riluzole |
| Rituximab |
08.02.03 |
Restricted Use
|
NICE TA174: Leukaemia (chronic lymphocytic, first line) - rituximab |
| Rituximab |
08.02.03 |
Restricted Use
|
NICE TA193: Leukaemia (chronic lymphocytic, relapsed) - rituximab |
| Rituximab |
08.02.03 |
Restricted Use
|
NICE TA137: Lymphoma (follicular non-Hodgkins) - rituximab |
| Rituximab |
08.02.03 |
Restricted Use
|
NICE TA110: Follicular lymphoma - rituximab Non-Hodgkins lymphoma - rituximab |
| Rituximab |
10.01.03 |
Restricted Use
|
NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Rituximab |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in patients with AF |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA261: Rivaroxaban for treatment of DVT |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA170: Rivaroxaban for the prevention of venous thromboembolism after total hip or knee replacement in adults |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA287: Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban: guidance |
| Roflumilast |
03.03.03 |
Restricted Use
|
NICE TA461: Roflumilast for treating severe chronic obstructive pulmonary disease |
| Romiplostim |
09.01.04 |
Restricted Use
|
NICE TA221: Thrombocytopenic purpura - romiplostim |
| Rucaparib |
08.02 |
Formulary
|
NICE TA 611 |
| Rucaparib |
08.02 |
Formulary
|
NG161COVID-19 rapid guideline delivery of systemic anticancer treatments |
| Ruxolitinib |
08.01.05 |
Non Formulary
|
NICE TA 289: Myelofibrosis (splenomegaly, symptoms) - ruxolitinib |
| Safinamide |
04.09.01 |
Restricted Use
|
NICE ES6 - Parkinson’s disease with motor fluctuations: safinamide |
| Sarilumab |
10.01.03 |
Restricted Use
|
COVID-19 rapid evidence summary: Sarilumab for COVID-19-ES34 |
| Sarilumab |
10.01.03 |
Restricted Use
|
NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis |
| Secukinumab |
13.05.03 |
Restricted Use
|
NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis |
| Secukinumab |
13.05.03 |
Restricted Use
|
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Secukinumab |
13.05.03 |
Restricted Use
|
NICE TA407: Secukinumab - active ankylosing spondylitis |
| Semaglutide |
06.01.02.03 |
Formulary
|
NG28- Type 2 diabetes in adults: management |
| Sodium Zirconium Cyclosilicate |
09.02.01.01 |
Restricted Use
|
Sodium zirconium cyclosilicate for treating hyperkalaemia |
| Somatropin |
06.05.01 |
Restricted Use
|
NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (review) |
| Somatropin |
06.05.01 |
Restricted Use
|
NICE TA64: Growth hormone deficiency (adults) - human growth hormone |
| Sorafenib |
08.01.05 |
Non Formulary
|
NICE TA189: Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) |
| Sunitinib |
08.01.05 |
Non Formulary
|
NICE TA169: Renal cell carcinoma - sunitinib |
| Sunitinib |
08.01.05 |
Non Formulary
|
NICE TA179: Gastrointestinal stromal tumours - sunitinib |
| Sunitinib |
08.01.05 |
Non Formulary
|
NICE TA178: Renal cell carcinoma |
| Tacrolimus ointment |
13.05.03 |
Restricted Use
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Tegafur with Uracil |
08.01.03 |
Non Formulary
|
NICE TA61: Capcitabine and tegafur - Colorectal cancer |
| Telaprevir |
05.03.03 |
Non Formulary
|
NICE TA252: Telaprevir for the treatment of genotype 1 chronic hepatitis C |
| Temozolomide |
08.01.05 |
Non Formulary
|
NICE TA23: Brain cancer - temozolomide |
| Temozolomide |
08.01.05 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Temsirolimus |
08.01.05 |
Non Formulary
|
NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal) |
| Temsirolimus |
08.01.05 |
Non Formulary
|
NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma |
| Tenofovir Disproxil |
05.03.01 |
Restricted Use
|
NICE TA173: Tenofovir disoproxil for the treatment of chronic hepatitis B |
| Teriflunomide |
08.02.04 |
Restricted Use
|
NICE TA 303: Teriflunomide for treating relapsing remitting multiple sclerosis |
| Thalidomide |
08.02.04 |
Restricted Use
|
NICE TA228 - Multiple Myeloma (first line) - bortezomib and thalidomide |
| Ticagrelor |
02.09 |
Restricted Use
|
NICE TA236 - Acute Coronary Syndromes - Ticagrelor |
| Ticagrelor |
02.09 |
Restricted Use
|
NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction |
| Tildrakizumab |
13.05.03 |
Restricted Use
|
|
| Tildrakizumab |
13.05.03 |
Restricted Use
|
|
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA238: Tocilizumab for the treatment of systemic juvenile arthritis |
| Tocilizumab |
10.01.03 |
Restricted Use
|
COVID-19 rapid evidence summary: Tocilizumab for COVID-19 ES33 |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA247: Tocilizumab for the treatment of rheumatoid arthritis |
| Tocilizumab |
10.01.03 |
Restricted Use
|
Tocilizumab for Giant Cell Arteritis TA518 |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idopathic arthritis |
| Tofacitinib |
01.05.03 |
Restricted Use
|
NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis |
| Tofacitinib |
10.01.03 |
Restricted Use
|
NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis |
| Tofacitinib |
10.01.03 |
Restricted Use
|
NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs |
| Tolvaptan |
06.05.02 |
Non Formulary
|
NICE TA358: Tolvapton for treating autosomal dominant polycystic kidney disease |
| Topotecan |
08.01.05 |
Non Formulary
|
NICE TA183: Cervical cancer (recurrent) - topotecan |
| Topotecan |
08.01.05 |
Non Formulary
|
NICE TA184: Lung cancer (small-cell) - topotecan |
| Topotecan |
08.01.05 |
Non Formulary
|
NICE TA91: Topotecan for ovarian cancer |
| Trabectedin |
08.01.05 |
Non Formulary
|
NICE TA185: Soft tissue sarcoma - trabectedin |
| Trabectedin |
08.01.05 |
Non Formulary
|
NICE TA222- ovarian cancer |
| Trastuzumab |
08.01.05 |
Non Formulary
|
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab |
| Trastuzumab |
08.01.05 |
Non Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Trastuzumab |
08.01.05 |
Non Formulary
|
NICE TA34: Breast cancer - trastuzumab |
| Ustekinumab |
01.05.03 |
Formulary
|
NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment |
| Ustekinumab |
01.05.03 |
Formulary
|
Ustekinumab for treating moderately to severely active ulcerative colitis |
| Ustekinumab |
10.01.03 |
Restricted Use
|
NICE TA340: Ustekinumab for treating active psoriatic arthritis |
| Ustekinumab |
13.05.03 |
Restricted Use
|
NICE TA340: Ustekinumab for treating active psoriatic arthritis |
| Ustekinumab |
13.05.03 |
Restricted Use
|
NICE TA180: Psoriasis - ustekinumab |
| Varenicline |
04.10.02 |
Formulary
|
NICE TA123: Varenicline |
| Vedolizumab |
01.05.03 |
Restricted Use
|
NICE TA352: Vedolizumab for treating moderately to severely active crohns disease after prior therapy |
| Vedolizumab |
01.05.03 |
Restricted Use
|
NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis |
| Venetoclax |
08.02 |
Formulary
|
NICE TA663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia |
| Venetoclax |
08.02 |
Formulary
|
NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia |
| Venetoclax |
08.02 |
Formulary
|
NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia |
| Zolpidem |
04.01.01 |
Non Formulary
|
NICE TAG 77 : Zaleplon, zolpidem and zopiclone for the management of insomnia |
| Zopiclone |
04.01.01 |
Restricted Use
|
NICE TA77 :Zaleplon, zolpidem and zopiclone for the management of insomnia |
